- $0.08m
- $5.65m
- $0.86m
Brief: Scisparc-Clearmind Medicine Collaboration Announces The Publication Of European Patent Application For Binge Behavior Psychedelic Combination Treatment
Brief: Scisparc Provides Updates On Status Of Spin-Off Of Its Advanced Clinical Stage Pharmaceutical Portfolio
Brief: Scisparc Ltd Entered Into Second Addendum To Merger Agreement With Automax Motors Ltd And Scisparc Merger Sub Ltd
Brief: Scisparc Signs Non-Binding Letter Of Intent To Sell Stake In Mitocarex
Brief: SciSparc Gets FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
Brief: Scisparc Takes Major Step Forward With Ind Application Submitted To The FDA For Phase Iib Clinical Trial For Tourette Syndrome Treatment
Brief: Scisparc Grants Global Rights For Pain Therapy To Biotech Company
Brief: SciSparc submitted IND Application To The FDA For SCI-110 Phase IIb Clinical Trial For Patients With Tourette Syndrome
Brief: Scisparc Announces Enrollment Of The First Five Patients In The Clinical Trial Of Its Innovative Sci-210 Treatment
Brief: Scisparc Finalizes $3 Mln Global Out-Licensing Agreement For Its Pain Therapy
Brief: Scisparc Updates Regarding The Status Of Automax Merger
Brief: Scisparc Mitocarex Confirms Role Of Its Drug Target In Non-Small Cell Lung Cancer
Brief: Scisparc Announces US Patent Application For Treating Metabolic Syndrome And Weight Loss
Brief: SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
Entered Into An Amendment To Bridge Loan Agreement With Automax Motors Ltd.
Brief: Scisparc Secures Grant Of European Patent
Brief: SciSparc To Acquire Israeli Vehicle Importer AutoMax
Brief: Clearmind Submits New International Patent Application For Preventing, Treating Depression
Brief: Scisparc Announces Enrollment Of First Patient For Its Clinical Trial